At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Folfirinox + regorafenibcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With RAS-mutated Metastatic Colorectal Cancer: a Dose-escalation, Phase I/II Trial
Institut du Cancer de Montpellier - Val d'Aurelle·interventional·Posted Feb 4, 2019·Updated Feb 27, 2026
In Brief
A Phase 2 clinical trial evaluating Folfirinox + regorafenib for Metastatic Colorectal Cancer. Completed, enrolled 13 participants across 4 sites.
Detailed Summary
Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMay 2019
Primary CompletionDec 2021
Study CompletionNov 2024
TodayJul 2026
First PostedFeb 4, 2019
Enrollment StartMay 14, 2019
Primary CompletionDec 2, 2021
Study CompletionNov 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.4 years ago
Interventions
Folfirinox + regorafenibcombination
folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days